US 11,779,575 B2
Use of Wnt inhibitor Wnt-C59 in preparation of drug for treating SCN5A mutation-induced dilated cardiomyopathy
Junbo Ge, Shanghai (CN); Aijun Sun, Shanghai (CN); Jingjing Hu, Shanghai (CN); and Kun Yang, Shanghai (CN)
Assigned to ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY, Shanghai (CN)
Appl. No. 17/637,455
Filed by ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY, Shanghai (CN)
PCT Filed Aug. 6, 2021, PCT No. PCT/CN2021/111105
§ 371(c)(1), (2) Date Feb. 23, 2022,
PCT Pub. No. WO2022/116583, PCT Pub. Date Jun. 9, 2022.
Claims priority of application No. 202011403201.8 (CN), filed on Dec. 4, 2020.
Prior Publication US 2022/0370428 A1, Nov. 24, 2022
Int. Cl. A61K 31/444 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/444 (2013.01) [A61P 9/04 (2018.01)] 8 Claims
 
1. A method of treating a SCN5A mutation-induced dilated cardiomyopathy (DCM), comprising preparing a drug wherein the drug comprises a Wnt inhibitor Wnt-C59.